Immunotherapy for treatment of corneolimbal squamous cell carcinoma in the horse
The goal of this study is to show the safety and efficacy of perilesional immunotherapy for treatment of corneolimbal squamous cell carcinoma. Once your horse in enrolled in the study, an injection of an immunotherapy will be performed around the tumor (sub-conjunctival) under standing sedation and using topical anesthesia. We will send home immunotherapy drops to be put in the eye with the tumor once a day for the duration of the study. Your horse will return every four weeks to repeat the injection for a total of three injections. Photos and measurements of the tumor will be taken at each recheck. If you your horse fails to respond to the immunotherapy, alternative treatments will be discussed.
condition(s)
eligibility information
A physical exam will be performed as well as blood work (complete blood count and serum chemistry) prior to enrollment. Your horse needs to be otherwise systemically healthy to be enrolled. A biopsy of the mass will also be performed at the first visit to confirm the diagnosis of squamous cell carcinoma. Once this is confirmed, your horse can be enrolled in the study and all costs are covered thereafter.
Enrollment Deadline
Enrollment ends September 29, 2023
contact information
